Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool.

Thrombosis research·2023
Same author

[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)].

Pneumologie (Stuttgart, Germany)·2020
Same author

Atrial fibrillation is frequent but does not affect risk stratification in pulmonary embolism.

Journal of internal medicine·2019
Same author

[Medicinal treatment of tricuspid valve regurgitation].

Herz·2017
Same author

Perivascular adipose tissue: epiphenomenon or local risk factor?

International journal of obesity (2005)·2017
Same author

[Chronic thromboembolic pulmonary hypertension: Recommendations of the Cologne Consensus Conference 2016].

Deutsche medizinische Wochenschrift (1946)·2016

Related Experiment Video

Updated: May 15, 2026

A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

Pulmonary embolism hotline 2012. Recent and expected trials.

S Konstantinides1, M Lankeit

  • 1Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Langenbeckstrasse 1, Bldg. 403, 55131 Mainz, Germany. stavros.konstantinides@unimedizin-mainz.de

Hamostaseologie
|January 23, 2013
PubMed
Summary

New oral anticoagulants and thrombolysis are advancing pulmonary embolism (PE) treatment. Studies are evaluating tenecteplase for intermediate-risk PE and new drugs like apixaban for long-term prophylaxis, offering safer options.

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Related Experiment Videos

Last Updated: May 15, 2026

A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Area of Science:

  • Cardiology
  • Pulmonology
  • Thrombosis Management

Background:

  • Acute pulmonary embolism (PE) management is rapidly evolving.
  • Intermediate-risk PE patients require optimized treatment strategies.

Purpose of the Study:

  • To evaluate thrombolytic treatment with tenecteplase versus placebo in normotensive patients with intermediate-risk PE.
  • To assess the efficacy and safety of new oral anticoagulants for PE treatment and secondary prophylaxis.

Main Methods:

  • The Pulmonary Embolism Thrombolysis (PEITHO) study randomized 1006 patients to tenecteplase or placebo.
  • Ongoing trials (AMPLIFY, HOKUSAI) are investigating apixaban and edoxaban for PE.
  • AMPLIFY-EXT demonstrated apixaban's efficacy in long-term PE prophylaxis.

Main Results:

  • PEITHO study results on clinical endpoints (death, haemodynamic collapse) are expected soon.
  • New oral anticoagulants like rivaroxaban and apixaban are approved for PE treatment and prophylaxis.
  • Low-dose aspirin shows potential for extended prophylaxis in specific patient groups.

Conclusions:

  • Advancements in thrombolysis and anticoagulation are improving PE management.
  • New oral anticoagulants offer effective and safer alternatives for PE treatment and long-term prophylaxis.
  • Further research is ongoing to refine treatment strategies for various PE risk profiles.